CXCL12/SDF-1 has been reported both as a stimulator and an antagonist of several perspectives of inflammatory response in type 2 diabetes and its complications and CXCL12/SDF-1might be a promising treatment target to improve islet engraftment (35). This evidence concerns the gene CXCL12 and type 2 diabetes mellitus.